CStone Pharma's (基石药业) Lock-Up Expiry - A Review of Valuation
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
583 Views
CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
741 Views
CStone Pharma's (基石药业) Lock-Up Expiry - Lack of Material Newsflow for Core Drug Candidates
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
746 Views
HK IPO Analytics 1H2019: MS and CICC Stand Out
At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
886 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
715 Views